Johnson & Johnson (JNJ) Q3 2026 Financial Results Summary
QuoteReporter
Johnson & Johnson (JNJ) Q3 2026: Revenue Growth Amidst Earnings Decline — Cautiously Optimistic
Johnson & Johnson (NYSE: JNJ) reported its Q3 2026 results, revealing a revenue growth of $1.4 billion or +5.9% year-over-year, with reported sales reaching $25.4 billion compared to $23.993 billion in Q3 2025. However, the company faced a significant decline in earnings per share (EPS), which fell to $0.09 from $2.12 in the prior year, reflecting a decrease of 95.8%.
This quarter presents a mixed bag for shareholders. While the revenue growth is a positive indicator of the company's operational momentum, the drastic drop in EPS raises concerns about profitability and the impact of one-time charges related to litigation and acquisitions. The adjusted EPS of $2.59 also fell short of the previous year's $2.80, marking a decline of 7.5%.
Key Financial Metrics:
- Reported Sales: $25.4 billion in Q3 2026 vs. $23.993 billion in Q3 2025 (+5.9% YoY)
- Net Earnings: $210 million in Q3 2026 vs. $5.152 billion in Q3 2025 (-95.9% YoY)
- EPS: $0.09 in Q3 2026 vs. $2.12 in Q3 2025 (-95.8% YoY)
- Adjusted EPS: $2.59 in Q3 2026 vs. $2.80 in Q3 2025 (-7.5% YoY)
- Free Cash Flow: ~$15.1 billion in Q3 2026 vs. $14.226 billion in Q3 2025
Dividend and Guidance Changes:
Johnson & Johnson has raised its full-year 2026 guidance, now estimating reported sales of $101.2 billion, which represents a growth of 7.4% at the midpoint. Additionally, the adjusted EPS guidance has been increased by $0.06 to $11.10, reflecting a 2.9% increase at the midpoint. This upward revision in guidance is a positive signal for investors, indicating management's confidence in the company's growth trajectory despite the current quarter's challenges.
Strategic Developments:
The company highlighted significant innovations during the quarter, including the market authorization of OTTAVA, the world's first table-integrated soft tissue robotic system, and the approval of IMAAVY for treating warm autoimmune hemolytic anemia. These advancements underscore Johnson & Johnson's commitment to enhancing its product offerings and addressing unmet medical needs.
Analyst View:
The mixed results present a cautious outlook for shareholders. The revenue growth is encouraging, suggesting that the company's core operations are performing well. However, the substantial decline in net earnings and EPS raises questions about the sustainability of profitability in the face of ongoing litigation costs and strategic acquisitions. Investors should closely monitor how these factors evolve in the coming quarters.
Forward Catalysts:
Looking ahead, investors should watch for the continued impact of Johnson & Johnson's innovative product launches and the effectiveness of its strategic investments in high-growth areas. Additionally, the company's ability to manage litigation costs and integrate recent acquisitions will be crucial in determining its financial performance in the next quarter. The upcoming earnings call will provide further insights into management's strategies and expectations for the remainder of 2026.
Here are the extracted tables from the provided press release:
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Note: Amounts are in millions)
| Q3 2026 | Q3 2025 | % Change | |
|---|---|---|---|
| Reported Sales | $25,399 | $23,993 | 5.9 % |
| Net Earnings | $210 | $5,152 | -95.9 % |
| EPS (diluted) | $0.09 | $2.12 | -95.8 % |
| Non-GAAP Operating Sales | 6.0 % | N/A | N/A |
| Adjusted Net Earnings | $6,339 | $6,801 | -6.8 % |
| Adjusted EPS (diluted) | $2.59 | $2.80 | -7.5 % |
| Free Cash Flow | ~$15,100 | $14,226 |
CONDENSED CONSOLIDATED BALANCE SHEETS
(Note: Amounts are in billions)
| October 2026 | July 29, 2026 | |
|---|---|---|
| Adjusted Operational Sales | 6.4% – 6.8% | 6.2% – 6.8% |
| Change vs. Prior Year | / 6.6% | 6.5% |
| Operational Sales | $100.5B – $100.9B | $100.9B / $100.7B |
| Change vs. Prior Year | 6.7% – 7.1% | 6.5% – 7.1% |
| Estimated Reported Sales | $101.0B – $101.4B | $101.4B / $101.1B |
| Change vs. Prior Year | 7.2% – 7.6% | 7.0% – 7.6% |
| Adjusted Operational EPS | $10.95 – $11.05 | $11.01 / $10.94 |
| Change vs. Prior Year | 1.5% – 2.4% | 0.7% – 2.1% |
| Adjusted EPS (Diluted) | $11.05 – $11.15 | $11.10 / $11.04 |
| Change vs. Prior Year | 2.4% – 3.3% | 1.6% – 3.0% |
These tables retain their original formatting and provide a clear view of the financial data presented in the press release.
Disclaimer
The content on MarketsFN.com is provided for educational and informational purposes only. It does not constitute financial advice, investment recommendations, or trading guidance. All investments carry risk and past performance does not guarantee future results. You are solely responsible for your investment decisions and should conduct independent research and consult a qualified financial advisor before acting. MarketsFN.com and its authors are not liable for any losses or damages arising from the use of this information.
